{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:35:51Z","timestamp":1793039751461,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"National Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.neuroscience.2026.10.036","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:07:17Z","timestamp":1792796837000},"page":"97-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["State transitions in amyotrophic lateral sclerosis: mechanistic convergence and biomarker-guided stratification"],"prefix":"10.1016","volume":"619","author":[{"given":"Mo","family":"Nasb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyab Hamid","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3307-1251","authenticated-orcid":false,"given":"Lamis","family":"Dayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.10.036_b0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: translating genetic discoveries into therapies","volume":"24","author":"Ak\u00e7imen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/jamaneurol.2024.5249","article-title":"Verdiperstat in amyotrophic lateral sclerosis: results from the randomized HEALEY ALS Platform Trial","volume":"82","author":"Andrews","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"10.1016\/j.neuroscience.2026.10.036_b0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S1474-4422(25)00109-7","article-title":"Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy","volume":"24","author":"Balendra","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.929151","article-title":"Longitudinal monitoring of amyotrophic lateral sclerosis by diffusion tensor imaging: power calculations for group studies","volume":"16","author":"Behler","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105323","article-title":"Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis","volume":"108","author":"Benatar","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.neuroscience.2026.10.036_b0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41582-024-00961-z","article-title":"The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology","volume":"20","author":"Benatar","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0040","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1093\/brain\/awac394","article-title":"Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal","volume":"146","author":"Benatar","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2026.10.036_b0045","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(25)00262-4","article-title":"Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bensimon","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2026.10.036_b0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-019-1443-5","article-title":"Potential roles of gut microbiome and metabolites in modulating ALS in mice","volume":"572","author":"Blacher","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.10.036_b0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ana.23937","article-title":"Stages of pTDP-43 pathology in amyotrophic lateral sclerosis","volume":"74","author":"Brettschneider","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0060","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41598-020-80370-6","article-title":"Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS","volume":"11","author":"Brodovitch","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0065","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/s41593-025-02050-w","article-title":"TDP-43 loss induces cryptic polyadenylation in ALS\/FTD","volume":"28","author":"Bryce-Smith","year":"2025","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0070","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1038\/s41467-024-49196-y","article-title":"Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target","volume":"15","author":"Caldi Gomes","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41593-017-0047-3","article-title":"TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS\/FTD","volume":"21","author":"Chou","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41467-022-35494-w","article-title":"Molecular subtypes of ALS are associated with differences in patient prognosis","volume":"14","author":"Eshima","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41582-024-01049-4","article-title":"Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis","volume":"21","author":"Faller","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117257","article-title":"Hypermetabolism is a reality in amyotrophic lateral sclerosis compared to healthy subjects","volume":"420","author":"Fayemendy","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0095","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2026.10.036_b0100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/jnnp-2023-332121","article-title":"Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case-control cohort","volume":"95","author":"Goutman","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.10.036_b0105","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(21)00414-2","article-title":"Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0110","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41582-023-00867-2","article-title":"The amyotrophic lateral sclerosis exposome: recent advances and future directions","volume":"19","author":"Goutman","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ana.27208","article-title":"Longitudinal metabolomics in amyotrophic lateral sclerosis implicates impaired lipid metabolism","volume":"98","author":"Guo","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108538","article-title":"Nuclear import receptors directly bind to arginine-rich dipeptide repeat proteins and suppress their pathological interactions","volume":"33","author":"Hutten","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0125","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41591-023-02788-5","article-title":"A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD","volume":"30","author":"Irwin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0130","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/s41593-025-02075-1","article-title":"C9orf72 hexanucleotide repeat expansions impair microglial response in ALS","volume":"28","author":"Masrori","year":"2025","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/21678421.2023.2215838","article-title":"PRECISION ALS\u2014an integrated pan-European patient data platform for ALS","volume":"24","author":"McFarlane","year":"2023","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00401-020-02252-5","article-title":"Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis","volume":"141","author":"Mehta","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0150","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1474-4422(25)00026-2","article-title":"Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics","volume":"24","author":"Mizielinska","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115402","article-title":"ALS molecular subtypes are a combination of cellular and pathological features learned by deep multiomics classifiers","volume":"44","author":"O\u2019Neill","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jcbfm.2011.147","article-title":"An 18-kDa translocator protein polymorphism explains differences in binding affinity of the PET radioligand PBR28","volume":"32","author":"Owen","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ana.26285","article-title":"Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development","volume":"91","author":"Paganoni","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123112","article-title":"High levels of neurofilament light and YKL-40 in cerebrospinal fluid are related to poor outcome in ALS","volume":"463","author":"Ros\u00e9n","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0180","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/jamaneurol.2025.0241","article-title":"Reldesemtiv in amyotrophic lateral sclerosis","volume":"82","author":"Shefner","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0185","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(25)00513-6","article-title":"Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series","volume":"405","author":"Shneider","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2026.10.036_b0190","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1111\/ene.15010","article-title":"Early diagnosis of amyotrophic lateral sclerosis by threshold tracking and conventional transcranial magnetic stimulation","volume":"28","author":"Tankisi","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13024-025-00890-5","article-title":"Entering the era of precision medicine to treat amyotrophic lateral sclerosis","volume":"20","author":"Theunissen","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0200","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1038\/s41467-023-41603-0","article-title":"C9orf72-ALS human iPSC microglia are pro-inflammatory and toxic to co-cultured motor neurons via MMP9","volume":"14","author":"Vahsen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0205","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1474-4422(24)00216-3","article-title":"Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double-blinded, placebo-controlled, multiple ascending dose study","volume":"23","author":"van den Berg","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0210","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.tins.2021.04.008","article-title":"Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis","volume":"44","author":"Van Harten","year":"2021","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0215","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41588-021-00973-1","article-title":"Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology","volume":"53","author":"van Rheenen","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuroscience.2026.10.036_b0220","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2026.2692737","article-title":"Microbiome and metabolites impact enteric and central nervous systems in amyotrophic lateral sclerosis","volume":"18","author":"Walton","year":"2026","journal-title":"Gut Microbes"},{"key":"10.1016\/j.neuroscience.2026.10.036_b0225","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1038\/s41467-018-05892-0","article-title":"Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference","volume":"9","author":"Young","year":"2018","journal-title":"Nat. Commun."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226007062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226007062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:44:02Z","timestamp":1793036642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226007062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":45,"alternative-id":["S0306452226007062"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.10.036","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State transitions in amyotrophic lateral sclerosis: mechanistic convergence and biomarker-guided stratification","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.10.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}